reason report
improv sni readi buy
bottom line yesterday regeneron sanofi announc
secondari offer approxim sanofi-own
common stock stock repurchas sny-own
stock sanofi current own approxim million
regeneron share intend sell million share
public offer plu addit greensho underwrit
share buy-back sanofi expect liquid nearli
stock share intend retain
residu sharehold could use fulfil sanofi futur expens
reimburs oblig regeneron sanofi exit occur
earlier expect agreement lock-up expir dec
liquid expect take multipl year dont believ
caus materi disrupt regn stock fact expect
larg investor take offer quickli expect
stock trade posit initi adjust next day
end regeneron futur share count reduc
compani increment initi leverag also lower
overal cost capit bp lower thu increas valu
remain share view share own
sanofi anoth institut make littl differ valu per
share stock slightli adjust model
incorpor chang outstand share cost capit net
cash non-oper incom balanc sheet item kept
revenu oper expens estim unchang base
chang price target remain unchang
reiter outperform rate regeneron stock also
slight tweak sni model reflect chang net cash invest
cash flow non-oper incom kept revenu oper
expens estim unchang price target sni chang
reiter market perform rate sanofi stock
compani inform svb leerink llc research
pleas refer page import disclosur price chart analyst certif
posit develop regn stock sever reason first
remov overhang regeneron stock occasion come convers
investor sanofi would dribbl equiti market expiri
lock-up thu cap upsid stock second elimin sanofi call option
acquisit interest regeneron sinc block equiti posit board
particip right refus regeneron equiti margin mean
possibl acquisit less remot sinc parti might
interest third end transact reduc regn share count approxim
thu immedi accret fourth transact mark first leverag
employ regeneron start reduc compani cost capit rang
diversifi peer immedi wacc improv furthermor like
convers compani initi short-term debt long-term convent debt may signal
activ deploy compani balanc sheet futur could see
increas valu final transact increas liquid float regn stock
occasion issu new investor addit float transpar
financi report true valu regeneron equiti becom appar
view secondari offer doesnt mean regn stock overvalu
facilit acceler sanofi near-term activ mani investor might argu
sanofi manag take advantag regeneron recent ralli ytd doesnt
want wait lock-up expir month acceler consist sanofi
state strategi free capit pursu accret complementari sanofi appear
take advantag strong liquid biotech equiti market particular
acceler implement strategi expect sit
new capit sanofi get liquid larg equiti posit gener signific
posit return initi invest origin believ
fundament driver decis sanofi desir acceler anticip initi
use close price may sanofi expect gener cash proce
sell equiti invest current cash
sanofi cash balanc sheet would enabl sanofi much larger
deal recent synthorx acquisit sanofi manag previous comment
 focu around new mechan asset could complementari
exist infrastructur on-going clinic develop expertis
earn call sanofi ceo paul hudson also indic person contractu
restrict prevent involv non-novarti gene therapi invest
end late februari suggest signific invest gene therapi platform
could possibl certainli expect deal decent size come month
sanofi addit sanofi announc follow public offer share repurchas
sanofi discontinu account ownership regeneron common share
equiti method sanofi still maintain ep growth guidanc constant exchang
chang revenu oper expens estim price target
unchang reiter op base yesterday announc slightli
tweak model reflect chang share outstand cost capit net cash non-
oper incom balanc sheet item kept revenu oper expens
estim unchang dilut share outstand estim decreas
non-gaap ep estim slightli increas remain larg
unchang updat non-gaap ep latest consensu
higher revenu forecast unchang higher
consensu higher combin price target remain
unchang reiter outperform rate regeneron stock
chang sni revenu oper expens estim price target
reiter mp incorpor sell ownership slight tweak
model reflect chang net cash invest cash flow non-oper incom kept
revenu oper expens estim unchang non-gaap ep estim slightli
increas price target chang reiter market
perform rate sanofi stock
price target regeneron stock rate outperform regeneron
veteran biopharmaceut compani grow strongli base success
first truli novel medicin dupix allerg diseas first product eylea continu
surpris investor taken grown market intraocular vegf vascular
endotheli growth factor antibodi treatment eylea contribut global sale
trump categori pioneer roch lucenti well cheaper altern
compound bevacizumab eylea also seem easili absorb launch novarti
beovu show sign continu growth multipl indic remain posit
eylea expect continu grow excit aspect compani
next wave innov antibodi notabl dupix approv adult
atop dermat asthma like receiv label expans multipl allerg diseas
indic expect dupix dupilumab gener revenu
peak signific upsid indic longer term regeneron
wholli own antibodi could contribut meaning revenu earn
growth period current compani invest mode result
earn cash flow convers revenu lag peer industri anticip
cash flow true earn improv period profit antibodi
collabor sanofi begin accumul
price target regeneron base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar high growth larg molecul biopharmaceut compani
price sale multipl large-cap high growth compani discount cash flow dcf
use averag large-cap larg molecul therapeut compani
rhhbi nv sni earn multipl ep appli current
ep estim give valu use slow growth
revenu multipl similar compani nv sni azn novo rhhbi
consensu sale appli revenu estim
give valu lastli dcf valuat given wacc
termin cash flow growth rate give present valu averag three
method current price target
risk view outlook valuat regeneron includ major chang
price reimburs coverag label competit posit eylea compani
main product today risk includ commerci develop disappoint
compani next partner program launch dupix kevzara well
continu weak demand price pressur compani cholesterol treatment praluent
lastli compani convert rel littl revenu cash flow today histori
return cash investor ultim may undermin valu stock
investor willing continu
rate sanofi market perform price target common stock
adr although sanofi new manag embark enthusiast re-
invent compani real progress chang compani portfolio
limit far sanofi like go benefit robust growth dupix
share regeneron ultim expect dupi meet exceed manag bullish
long-term revenu forecast howev opportun off-set cautiou view
compani franchis consensu aubagio rare diseas
vaccin cardiovascular product reason posit compani
opportun oncolog sarclisa doesnt realli move needl
low- mid-single-digit top-lin growth new manag sanofi capabl
improv profit past compani infrastructur proven stubbornli
resist chang final like almost everi compani industri sanofi appear
contempl fundament restructur busi spinout consum
establish product busi feasibl futur unclear whether compani
abl achiev chang given polit environ oper even
would like occur sever year competitor would still leav question
breadth potenti mid- late-stag pipelin
rate sanofi stock market perform valuat sanofi stock adr base
three approach normal employ calcul price target coverag compani
three approach employ dcf-base valuat price earn multipl
price sale multipl dcf base valuat consist expect cash flow
end use wacc termin growth rate give us
valu per share common stock price earn approach appli
current peer compani multipl ep appli ep estim sanofi
give fair valu common stock lastli price sale multipl use similar
group compar compani similar product portfolio growth outlook give us fair
valu per share overal averag per share adr although
scenario sni worth significantli estim believ
re-pric would requir signific progress and/or improv compani still
main risk valuat forecast sanofi compani core busi
erod faster farther forecast stand expect compani
establish medicin diabet franchis continu erod revenu loss
area match revenu gain dupix expect compani larg rare diseas
hemophilia busi grow slowli base new product launch offset
continu revenu loss matur product franchis face intensifi competit
challeng slow revenu growth fail materi revenu eros
matur busi acceler due increas discount greater market share loss
compani revenu perform could fall short expect similarli
forecast dupix incorpor multipl new market new age cohort new
indic price new pos-adjust forecast indic fail
pivot trial market share penetr achiev expect key diseas
atop dermat asthma dupix sale could fall short forecast lastli
forecast signific improv profit reduct share count sanofi
contribut earn outlook challeng margin improv trend
 fund higher expect commerci cost next year would
svb leerink research compani file zack factset consensu
svb leerink research compani file zack factset consensu
sec gov compani websit present svbl analysi
follow safeti
bla file
us approv
potenti bla file
phase result
top-line pivot data
phase data
phase data
interim result
studi
phase data
phase data
phase data
phase data
phase data
phase data
data
phase data
phase data
phase data
brand
type event
event trial detail
date known
up/down
expect
fda decis pediatr ad patient
phase result follow safeti
sbla file
us regulatori file
potenti bla file
full data expect
updat phase data potenti
combo immunotherapi present
futur medic confer
manag report phase data futur
svb leerink llc equiti research compani file
million
svb leerink llc partner research compani file
million
good sold
research develop
sell gener administr
collabor manufactur
 total revenu
sg total revenu
svb leerink llc research compani file
analysi stock price svb leerink target regeneron
method high growth larg cap biopharma ep multipl forma
ep rhhbi nv sni
svb leerink forma ep estim
impli price ep
equiti
number period
method larg cap biopharma forward multipl appli expect
revenu
larg cap high growth biopharma price/sal multipl
svb leerink revenu forecast
impli ev revenu
share count
ev per share
expect net per share
net expect valu per share
equiti
number period
impli share price
present valu po adjust flow
pv termin valu
net
share count
averag method
svb leerink llc research compani file factset
million
svb leerink research compani file
million
sale
total expens exclud
 total revenu
sg total revenu
svb leerink research compani file
sale
total expens exclud
 total revenu
sg total revenu
analysi stock price svb leerink target sanofi
method current larg cap biopharma stock multipl ep appli svbl ep estimate
svb leerink forma ep estim dilut sni
price
method valu base price sale multipl peer larg cap biopharma stock
svb leerink sni revenu estimate mm less partner product
impli sni market cap mm estimate sale
anticip share count ye mm
per share valu
proport valu regeneron ownership
method svb leerink probabl adjust dcf adjust net wacc termin
current svb leerink dcf sanofi marketed/l stage program
proport valu regeneron ownership
anticip share count ye mm
per share valu
sourc svb leerink llc estim compani file factset
